Cargando…

Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?

With the rapid scale up of antiretroviral therapy, there is a dramatic decline in HIV related morbidity and mortality in both developed and developing countries. Several new safe antiretroviral, and newer class of drugs and monitoring assays are developed recently. As a result the treatment guidelin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumarasamy, N., Patel, Atul, Pujari, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284090/
https://www.ncbi.nlm.nih.gov/pubmed/22310814
http://dx.doi.org/10.4103/0971-5916.92626
_version_ 1782224317951508480
author Kumarasamy, N.
Patel, Atul
Pujari, Sanjay
author_facet Kumarasamy, N.
Patel, Atul
Pujari, Sanjay
author_sort Kumarasamy, N.
collection PubMed
description With the rapid scale up of antiretroviral therapy, there is a dramatic decline in HIV related morbidity and mortality in both developed and developing countries. Several new safe antiretroviral, and newer class of drugs and monitoring assays are developed recently. As a result the treatment guideline for the management of HIV disease continue to change. This review focuses on evolving science on Indian policy - antiretroviral therapy initiation, which drugs to start with, when to change the initial regimen and what to change.
format Online
Article
Text
id pubmed-3284090
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-32840902012-02-24 Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to? Kumarasamy, N. Patel, Atul Pujari, Sanjay Indian J Med Res Review Article With the rapid scale up of antiretroviral therapy, there is a dramatic decline in HIV related morbidity and mortality in both developed and developing countries. Several new safe antiretroviral, and newer class of drugs and monitoring assays are developed recently. As a result the treatment guideline for the management of HIV disease continue to change. This review focuses on evolving science on Indian policy - antiretroviral therapy initiation, which drugs to start with, when to change the initial regimen and what to change. Medknow Publications & Media Pvt Ltd 2011-12 /pmc/articles/PMC3284090/ /pubmed/22310814 http://dx.doi.org/10.4103/0971-5916.92626 Text en Copyright: © The Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kumarasamy, N.
Patel, Atul
Pujari, Sanjay
Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
title Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
title_full Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
title_fullStr Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
title_full_unstemmed Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
title_short Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
title_sort antiretroviral therapy in indian setting: when & what to start with, when & what to switch to?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284090/
https://www.ncbi.nlm.nih.gov/pubmed/22310814
http://dx.doi.org/10.4103/0971-5916.92626
work_keys_str_mv AT kumarasamyn antiretroviraltherapyinindiansettingwhenwhattostartwithwhenwhattoswitchto
AT patelatul antiretroviraltherapyinindiansettingwhenwhattostartwithwhenwhattoswitchto
AT pujarisanjay antiretroviraltherapyinindiansettingwhenwhattostartwithwhenwhattoswitchto